Why are you ignoring the fact that 90 percent of patients in the trial were treated with DCVAX? There is no control in the trial.
99 patients were assigned to receive placebo until progression. That is the control arm. This is clinical trials 101.
If Merck runs a first line trial with K where it is already approved for second line do they cry foul that the trial failed because most all control took K after progression? No. But you are doing exactly that.
That post progression treatment confounds OS is a problem, Life is a bitch. Design better trials.
The P3 was designed to show PFS. As such the crossover did not matter. That was all on NWBO.
Market Data 
Markets 
AI
